Evidence map›Paper›PMID 41924924›Full record

ArticleHaematologica2026

Hypomethylating agents plus venetoclax

Guillaume Berton, Jan Philipp Bewersdorf, Julia Gilhodes, Alexandre Iat, Amel Soua, Daniel J DeAngelo, Leora Boussi, Rory M Shallis, Andrius Žučenka, Rebecca P Bystrom and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Guillaume BertonAix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille.
Jan Philipp BewersdorfYale University, New Haven, CT.
Julia GilhodesAix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille.
Alexandre IatAix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille.
Amel SouaAix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille.
Daniel J DeAngeloDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Leora BoussiMemorial Sloan Kettering Cancer Center, New York, NY.
Rory M ShallisMoffitt Cancer Center, Tampa, FL.
Andrius ŽučenkaHematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos and Vilnius University, Faculty of Medicine, Vilnius, Lithuania.
Rebecca P BystromDuke University Medical Center, Durham, NC.
Kelly LingDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Luis E AguirreDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Richard M StoneDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Marlise R LuskinDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Jacqueline S GarciaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Eric S WinerDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Evan C ChenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Martha WadleighDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Lourdes MendezYale University, New Haven, CT.
Nikolai PodoltsevYale University, New Haven, CT.
Urbain Tauveron-JalenquesService d'hématologie et de thérapie cellulaire, CHU Clermont-Ferrand, Clermont-Ferrand.
Luca LaninoYale University, New Haven, CT.
Eytan SteinMemorial Sloan Kettering Cancer Center, New York, NY.
Amer M ZeidanYale University, New Haven, CT.
Edouard ForcadeCHU de Bordeaux, Service Hématologie Clinique et Thérapie Cellulaire, UMR 5164, F-33000 Bordeaux.
Thomas CluzeauHematology Department, Nice University Hospital, Cote d'Azur University, Nice.
Pierre-Yves DumasCHU Bordeaux, Service d'Hématologie Clinique et de Thérapie Cellulaire, BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, Université de Bordeaux, Bordeaux.
Mael HeibligHospices Civils de Lyon, Hôpital Lyon Sud, Service d'hématologie Clinique Lyon France.
Raynier DevillierAix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille.
Shai ShimonyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
Aaron D GoldbergMemorial Sloan Kettering Cancer Center, New York, NY.
Maximilian StahlYale University, New Haven, CT.
Sylvain GarciazAix-Marseille University, Inserm, CNRS, Institut Paoli-Calmettes, CRCM, Marseille. garciazs@ipc.unicancer.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41924924
PMCPMC13628006

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.